Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis.
Adaptive immune receptor repertoire
Anti-drug antibody
B-cell receptor
Interferon beta
Multiple sclerosis
Next generation sequencing
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 09 2022
15 09 2022
Historique:
received:
19
03
2022
revised:
16
05
2022
accepted:
10
07
2022
pubmed:
20
7
2022
medline:
10
8
2022
entrez:
19
7
2022
Statut:
ppublish
Résumé
A significant proportion of multiple sclerosis (MS) patients treated with interferon beta-1a (Rebif™) develop anti-drug antibodies (ADA) with a negative impact on treatment efficacy. We hypothesized that high-throughput B-cell receptor (BCR) repertoire analysis could be used to predict and monitor ADA development. To study this we analyzed 228 peripheral blood samples from 68 longitudinally followed patients starting on interferon beta-1a. Our results show that whole blood BCR analysis does not reflect, and does not predict ADA development in MS patients treated with interferon beta-1a. We propose that BCR analysis of phenotypically selected cell subsets or tissues might be more informative.
Identifiants
pubmed: 35853357
pii: S0165-5728(22)00127-8
doi: 10.1016/j.jneuroim.2022.577932
pii:
doi:
Substances chimiques
Antibodies
0
Receptors, Antigen, B-Cell
0
Interferon beta-1a
XRO4566Q4R
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
577932Informations de copyright
Copyright © 2022. Published by Elsevier B.V.